FNY Investment Advisers LLC Has $761,000 Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

FNY Investment Advisers LLC grew its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 75.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 133,591 shares of the company's stock after purchasing an additional 57,625 shares during the period. FNY Investment Advisers LLC owned about 0.23% of Ginkgo Bioworks worth $761,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Ginkgo Bioworks by 780.6% during the fourth quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock valued at $36,967,000 after purchasing an additional 3,336,964 shares during the last quarter. Erste Asset Management GmbH lifted its holdings in shares of Ginkgo Bioworks by 47.9% during the fourth quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock valued at $6,979,000 after purchasing an additional 239,332 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks by 357.4% during the fourth quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after purchasing an additional 523,571 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Ginkgo Bioworks by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 437,025 shares of the company's stock valued at $4,294,000 after purchasing an additional 20,394 shares during the last quarter. Finally, Monaco Asset Management SAM lifted its holdings in shares of Ginkgo Bioworks by 3.9% during the fourth quarter. Monaco Asset Management SAM now owns 384,664 shares of the company's stock valued at $3,777,000 after purchasing an additional 14,539 shares during the last quarter. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Stock Down 3.8%

Shares of NYSE DNA opened at $8.94 on Monday. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.00 and a 12 month high of $18.55. The company has a market cap of $523.22 million, a price-to-earnings ratio of -0.68 and a beta of 1.25. The business has a fifty day simple moving average of $7.61 and a 200-day simple moving average of $9.09.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The business had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. As a group, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.